InflaRx NV to Prioritize Izicopan Development in Hidradenitis Suppurativa and I&I, Plans Workforce Reduction, China PK Bridging Study, and Cost Structure Optimization to Extend Cash Runway to Mid-2027

Reuters · 4d ago

Please log in to view news